Traditional Chinese Medicine As the Preventive and Therapeutic Remedy for COVID-19

Overview

Journal Curr Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2023 Mar 31

PMID 36999715

Authors

Amin Gasmi

Torsak Tippairote

Pavan Kumar Mujawdiya

Alain Menzel

Roman Lysiuk

Mariia Shanaida

Larysa Lenchyk

Massimiliano Peana

Geir Bjorklund

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic still has tremendous impacts on the global socio-economy and quality of living. The traditional Chinese Medicines (TCM) approach showed encouraging results during previous outbreaks of Severe Acute Respiratory Syndrome-related Coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). With limited treatment availability, TCM herbs and formulations could be useful to reduce COVID-19 symptoms and potential sources for discovering novel therapeutic targets. We reviewed 12 TCM herbs and formulations recommended for COVID-19 management by the National Health Commission and as National Administration of Traditional Chinese Medicine of the People's Republic of China. This article explored the Chinese national authorities' guidelines from 2003 to 2020, the scientific data in public databases for the recommended TCM remedies, and their potential mechanistic actions in COVID-19 management. Several TCM herbs and formulations could potentially benefit COVID-19 management. The recommended TCM oral preparations list includes , and ; the recommended injection preparations comprise Xiyanping , and . TCM remedies are viable options for symptom alleviation and management of COVID-19. The current SARS-CoV-2 pandemic presents an opportunity to find novel therapeutic targets from TCM-active ingredients. Despite the recommendations in Chinese National guidelines, these remedies warrant further assessments in well-designed clinical trials to ascertain their efficacy in the treatment of COVID-19.

Citing Articles

Effectiveness of seven oral traditional Chinese medicines against mild or moderate COVID-19: An updated systematic review and network meta-analysis.

Zhang T, Li T, Zhao F, Li T, Zhang M, Jin P Heliyon. 2024; 10(15):e35081.

PMID: 39170141 PMC: 11336365. DOI: 10.1016/j.heliyon.2024.e35081.

Ayurvedic and Chinese Herbs against Coronaviruses.

Gasmi A, Kanwal S, Oliinyk P, Lysiuk R, Shanaida M, Benahmed A Curr Pharm Des. 2024; 30(21):1681-1698.

PMID: 38685809 DOI: 10.2174/0113816128269864231112094917.

References

Yang Y, Peng F, Wang R, Yange M, Guan K, Jiang T . The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020; 109:102434. PMC: 7126544. DOI: 10.1016/j.jaut.2020.102434. View

Zhang D, Wu K, Zhang X, Deng S, Peng B . In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. J Integr Med. 2020; 18(2):152-158. PMC: 7102521. DOI: 10.1016/j.joim.2020.02.005. View

Totura A, Bavari S . Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov. 2019; 14(4):397-412. PMC: 7103675. DOI: 10.1080/17460441.2019.1581171. View

Gasmi A, Peana M, Pivina L, Srinath S, Benahmed A, Semenova Y . Interrelations between COVID-19 and other disorders. Clin Immunol. 2020; 224:108651. PMC: 7833539. DOI: 10.1016/j.clim.2020.108651. View

Araf Y, Akter F, Tang Y, Fatemi R, Parvez M, Zheng C . Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022; 94(5):1825-1832. PMC: 9015557. DOI: 10.1002/jmv.27588. View

Hossain M, Hassanzadeganroudsari M, Apostolopoulos V . The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines?. Expert Rev Vaccines. 2021; 20(6):635-638. PMC: 8074646. DOI: 10.1080/14760584.2021.1915140. View

Bakowski M, Beutler N, Wolff K, Kirkpatrick M, Chen E, Nguyen T . Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nat Commun. 2021; 12(1):3309. PMC: 8175350. DOI: 10.1038/s41467-021-23328-0. View

Sultana J, Crisafulli S, Gabbay F, Lynn E, Shakir S, Trifiro G . Challenges for Drug Repurposing in the COVID-19 Pandemic Era. Front Pharmacol. 2020; 11:588654. PMC: 7677570. DOI: 10.3389/fphar.2020.588654. View

Gasmi A, Peana M, Noor S, Lysiuk R, Menzel A, Benahmed A . Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. Appl Microbiol Biotechnol. 2021; 105(4):1333-1343. PMC: 7847229. DOI: 10.1007/s00253-021-11094-4. View

10.

Gong W, Zhou T, Wu S, Ye J, Xu J, Zeng F . A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19. J Infect Chemother. 2021; 27(6):876-881. PMC: 7894089. DOI: 10.1016/j.jiac.2021.02.018. View

11.

Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R . Addendum: The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2022; 12(1):1996. PMC: 8805134. DOI: 10.1038/s41598-022-05835-2. View

12.

Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R . The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021; 11(1):11022. PMC: 8155021. DOI: 10.1038/s41598-021-90551-6. View

13.

Lai C, Chen C, Wang C, Chen K, Wang Y, Hsueh P . Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2021; 76(8):1962-1968. PMC: 8083728. DOI: 10.1093/jac/dkab093. View

14.

Al-Abdouh A, Bizanti A, Barbarawi M, Jabri A, Kumar A, Fashanu O . Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Contemp Clin Trials. 2021; 101:106272. PMC: 7789823. DOI: 10.1016/j.cct.2021.106272. View

15.

Ling C . Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2). J Integr Med. 2020; 18(2):87-88. PMC: 7129043. DOI: 10.1016/j.joim.2020.02.004. View

16.

Yi L, Li Z, Yuan K, Qu X, Chen J, Wang G . Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J Virol. 2004; 78(20):11334-9. PMC: 521800. DOI: 10.1128/JVI.78.20.11334-11339.2004. View

17.

Li T, Peng T . Traditional Chinese herbal medicine as a source of molecules with antiviral activity. Antiviral Res. 2012; 97(1):1-9. PMC: 7114103. DOI: 10.1016/j.antiviral.2012.10.006. View

18.

Lin L, Hsu W, Lin C . Antiviral natural products and herbal medicines. J Tradit Complement Med. 2014; 4(1):24-35. PMC: 4032839. DOI: 10.4103/2225-4110.124335. View

19.

Zhao F, Yang Z, Wang N, Jin K, Luo Y . Traditional Chinese Medicine and Western Medicine Share Similar Philosophical Approaches to Fight COVID-19. Aging Dis. 2021; 12(5):1162-1168. PMC: 8279530. DOI: 10.14336/AD.2021.0512. View

20.

Luo H, Gao Y, Zou J, Zhang S, Chen H, Liu Q . Reflections on treatment of COVID-19 with traditional Chinese medicine. Chin Med. 2020; 15:94. PMC: 7468089. DOI: 10.1186/s13020-020-00375-1. View